Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02655822 · ClinicalTrials.gov registry record · Phase 1
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
A Phase 1 study, sponsored by Corvus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 502
- Enrollment target
NCT02655822 is a Phase 1 study that has completed, run by Corvus Pharmaceuticals. The registered enrollment target is 502 participants.
The verdict
NCT02655822, a Phase 1 study, has completed, sponsored by Corvus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 502 participants
- Enrollment target
Study Summary
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.
Interventions
- DRUG Ciforadenant
- DRUG Ciforadenant + atezolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 502 participants |
| Start Date | 2016-01 |
| Est. Completion | 2021-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02655822
The ClinicalTrials.gov registry entry for NCT02655822 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 502 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corvus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ciforadenant is the first listed.
NCT02655822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02655822 about?
NCT02655822 is a clinical study titled "Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers". This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single a...
What is the current status of trial NCT02655822?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 502 participants. The study started on 2016-01. Estimated completion is 2021-07.
What interventions are being tested in trial NCT02655822?
The interventions under investigation include: Ciforadenant (DRUG), Ciforadenant + atezolizumab (DRUG).
Who is sponsoring clinical trial NCT02655822?
This trial is sponsored by Corvus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.